We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
47 hedge funds and large institutions have $64.9M invested in Crescent Biopharma in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 20 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
42% more call options, than puts
Call options by funds: $1.08M | Put options by funds: $763K
0.03% less ownership
Funds ownership: 0.61% → 0.58% (-0.03%)
10% less capital invested
Capital invested by funds: $72.5M → $64.9M (-$7.58M)
19% less funds holding
Funds holding: 58 → 47 (-11)
55% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 20
67% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 15
Holders
47
Holders Change
-11
Holders Change %
-18.97%
% of All Funds
0.82%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
9
Reduced
20
Closed
15
Calls
$1.08M
Puts
$763K
Net Calls
+$320K
Net Calls Change
+$188K
Top Buyers
| 1 |
Two Sigma Investments
New York
|
+$578K |
| 2 |
Franklin Resources
San Mateo,
California
|
+$340K |
| 3 |
VF
Virtu Financial
New York
|
+$115K |
| 4 |
D.E. Shaw & Co
New York
|
+$109K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$76.2K |
Top Sellers
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$581K |
| 2 |
Millennium Management
New York
|
-$505K |
| 3 |
JP Morgan Chase
New York
|
-$494K |
| 4 |
E
Ergoteles
New York
|
-$373K |
| 5 |
Renaissance Technologies
New York
|
-$342K |
